MADISON, WIS, September 28, 2016 – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company and the leading developer and manufacturer of induced pluripotent stem cell (iPSC) products, today announced a new venture, named Opsis Therapeutics. Formed on July 31, Opsis Therapeutics is focused on discovering and developing novel medicines to treat patients suffering from retinal diseases. [Read more…]
Cellular Dynamics to Realign Business Units to Better Serve Therapeutic and Life Science Customers
(MADISON, Wis.)Â Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced that effective September 1, 2016 the company operations will be divided into two equally important business units. Emile Nuwaysir, PhD, President and Chief Operating Officer of CDI, will lead the Therapeutics Business Unit. The Life Science business unit will be led by Dr. Bruce Novich, Executive Vice President and General Manager. Dr. Novich is also the Division President, FUJIFILM North America Corporation Corporate New Business Development Division. [Read more…]
FUJIFILM Expands Its Reign in Regenerative Medicine
It has been a major week in the stem cell industry, with partnerships, licensing deals, and pre-clinical findings recently announced. Check out the latest coverage below. [Read more…]
Cynata and FUJIFILM Sign Non-binding Development and Commercialisation Term Sheet
Melbourne, Australia; 5 September 2016 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced the execution of a term sheet with FUJIFILM Corporation of Japan for the development and commercialisation of certain Cynata technology, including Cynata’s lead induced pluripotent stem cell (iPSC) derived therapeutic mesenchymal stem cell (MSC) product, CYP-001. Pursuant to the term sheet, the parties will work together to seek to finalise a definitive agreement. If the parties enter into a definitive agreement, Cynata expects it to be finalised in the fourth quarter of 2016. [Read more…]
Top Moments from “Fantastic Friday” at the World Stem Cell Summit (Day 2)
*Photo courtesy of Mayo Clinic. Source: https://flic.kr/p/BZSvVA
“Speed Dating” for Investors, De-extinction, and New Business Initiatives
Today was another incredible day a the World Stem Cell Summit (#WSCS15). Because of the jam-packed scheduled that runs from 7:15am breakfast networking through to an evening social, it is affectionately called “Fantastic Friday.” The day launched with speakers such as Dr. Joshua Hare and Dr. Tatsuya Shimizu discussing how mesenchymal stem cells (MSCs) can be used to repair and regenerate the human heart, either by directly stimulating the micro-environment or by stimulating the activity of muscle stem cells. Shortly thereafter, talks expanded to focus on other stem cell types, including induced pluripotent stem cells (iPCSs), which were explored in greater detail during a lunch-time “Japan Symposium” that featured presenters from FUJIFILM Corporation, Ajinomoto Co., Inc., Cyfuse Biomedical, and Kyoto University. [Read more…]